Galera Therapeutics, Inc. Operating Income Loss

• Galera Therapeutics, Inc. showed an increase of +87.4% in Operating Income Loss from 2024 to 2025.
• This data is from Galera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Galera Therapeutics, Inc.'s Operating Income Loss has grown by 89.5%.
• Historical annual values: Fiscal year 2025: -$2.54 million | Fiscal year 2024: -$20.16 million | Fiscal year 2023: -$49.26 million | Fiscal year 2022: -$51.23 million | Fiscal year 2021: -$73.37 million | Fiscal year 2020: -$70.55 million | Fiscal year 2019: -$50.69 million | Fiscal year 2018: -$24.26 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026